Seneca Biopharma, Inc.

Jan 25, 2021

Seneca Biopharma Regains Compliance with NASDAQ Listing Requirements

Dec 18, 2020

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Seneca Biopharma, Inc.

Dec 15, 2020

Seneca Biopharma Granted 180-Day Extension by NASDAQ to Regain Compliance with Bid Price Rule

Nov 10, 2020

Seneca Biopharma Reports 2020 Third Quarter Results

Sep 10, 2020

Seneca Biopharma, Inc. Announces Completion of Phase II Clinical Study in China for the Treatment of Ischemic Stroke

Sep 02, 2020

Letter from Seneca Biopharma's Executive Chairman

May 27, 2020

Seneca Biopharma Announces the Closing of its $5 Million Registered Direct Offering

May 22, 2020

Seneca Biopharma Reports Receipt of Warrant Exercise Proceeds

May 22, 2020

Seneca Biopharma Announces Pricing of $5 Million Registered Direct Offering Priced At-the-Market

Apr 09, 2020

Seneca Biopharma Announces Results of Meeting with FDA Regarding the Design of Phase 3 Trial for NSI-566 in ALS

Apr 03, 2020

Seneca Biopharma, Inc. Announces the Completion of Stem Cell Manufacturing Facility in China

Apr 01, 2020

Seneca Biopharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Apr 01, 2020

Seneca Biopharma Announces Executive Appointments and Key Promotion